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We report a case of a young patient in whom a sirolimus-eluting stent was implanted on the culprit left anterior descending
coronary artery at primary percutaneous coronary intervention (PCI) for acute myocardial infarction. Nine months later she
suﬀered from a reinfarction due to the late stent thrombosis despite a continuous antiplatelet therapy with aspirin and clopidogrel.
A cluster of factors that might have contributed to the development of the stent thrombosis were identiﬁed: suboptimal PCI
technique, complete stent fracture, and clopidogrel resistance. The obstructed stent was successfully reopened by repeat PCI, while
the clopidogrel maintenance dosage was doubled to 150mg daily for the following year. The further long-term clinical course was
uneventful.
Copyright © 2009 I. Kranjec and A. Cerne. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Predictors of the drug-eluting stent (DES) thrombosis (ST)
fall usually into four categories: (1) procedural factors (e.g.,
incomplete stent expansion), (2) drug eﬀects (e.g., delayed
vessel wall healing), (3) DES platform (e.g., hypersensitivity
tothepolymer),and(4)antiplateletactivity(e.g.,clopidogrel
resistance). Recent investigation of sirolimus-eluting stents
(SES) using optical coherence tomography discovered that
only 16% of all stent struts were completely endothelialized
at 6-month follow-up. Moreover, distinct thrombi appeared
in some of the SESs though ie of the patients suﬀered any
harmful consequences [1]. It was concluded that additional
mechanisms along with thrombogenic struts would be
needed to trigger the ST.
We describe, thus, a case of the young patient in whom
the SES was implanted on the culprit LAD artery at primary
PCI for the acute myocardial infarction (MI). A cluster
of unfavorable factors resulted in the late ST despite a
continuous double antiplatelet therapy. A repeat PCI was
chosen to open the clogged stent with a good long-term
result.
2.CaseReport
A 38-year-old female with hypertension, hypercholes-
terolemia, and positive family history presented to the ED
one hour after the onset of a severe chest discomfort.
Her ECG showed marked ST-segment elevations in leads I,
aVL, V1–4. She was taken immediately to the catheterization
laboratoryafterbeinggivennitroglycerin,morphine,aspirin,
and UFH. Angiography revealed a tight thrombotic lesion
of the proximal LAD with a TIMI grade 2 blood ﬂow
(Figure 1(a)). After additional ACT-guided UFH and 600mg
of clopidogrel, a JL 3.5 F6 guiding catheter (Cordis, Miami,
Fla, USA) was used to intubate the LCA, a 0.014-inch Asahi
soft guide wire (Abbot, Redwood City, Calif, USA) was
introduced into the distal LAD, a 2.0 × 20mm Mercury
balloon (Abbot, Redwood City, Calif, USA) was inﬂated
once at 7 At to pre-dilate the lesion, and ﬁnally a 2.5 ×
18mmSES(Cypher,Cordis,Miami,FL,USA)wasimplanted
at 16 At on the proximal LAD. The angiographic control
showed a good result (Figure 1(b)) and, as a result, no
attempt was made to expand the stent with a noncompliant
balloon.2 Case Reports in Medicine
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Figure 1: Consecutive coronary angiograms are shown in the LAO
view. (a) Tight, thrombotic lesion (arrow) of the angulated part
of the LAD artery. (b) Good angiographic result is achieved after
implantation of a 2.5 × 18mm sirolimus-eluting stent. (c) Throm-
botic occlusion (arrow) 9 months after the stent implantation. (d)
Final angiographic result after successive inﬂations of a 3.0×20mm
noncompliant balloon.
(a) (b)
Figure 2: IVUS images of the LAD artery beyond the proximal
(a) and distal borders (b) of the stented segment are shown after
the occlusive thrombus was mechanically removed. A large and
predominantly ﬁbrous plaque (arrows) narrows the vessel lumen
particularly at distal site.
Following the hospital discharge, the patient was
instructed to take daily aspirin 100mg for life, clopidogrel
75mg for one year, bisoprolol 2.5mg, ramipril 2.5mg, and
atorvastatin 10mg. She was doing well until 280 days later
whenshewasawakenedearlyinthemorningbytheintensive
chest pain accompanied by sweating and nausea. At the ED,
her heart rate was 60/min, blood pressure 90/60mm Hg,
(a) (b)
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Figure 3: Successive IVUS images of the LAD artery from proximal
(a) to distal part (d) of the fractured stent are shown after
the occlusive thrombus was mechanically removed. (a) Complete,
transverse fracture is seen with a spiral distortion of stent struts
(parallel arrows). (b) Stent gap with totally missing struts. (c) Re-
appearanceofafewstruts(orthogonalarrows).(d)Intactdistalpart
of the stent.
respiratory rate 18/min, and there were no pulmonary rales.
The ECG demonstrated signiﬁcant ST-segment re-elevations
in leads V3–6. She received similar medication as previously,
and was transferred to our catheterization laboratory again.
The repeat angiography showed a thrombotic occlusion of
the implanted stent (Figure 1(c)). An EBU 3.75F6 Launcher
guiding catheter (Medtronic, Minneapolis, Minn, USA) was
used to engage the left main coronary artery, a 0.014” BMW
guide wire (Abbot, Redwood City, Calif, USA) crossed the
stent struts easily, and a 2.0 × 20mm Mercury balloon
(Abbot, Redwood City, Calif, USA) was gently inﬂated
at 6 At to reopen the LAD. At this point, the IVUS
using the Atlantis 40MHz transducer (Boston Scientiﬁc,
Maple Grove, Minn, USA) with a motorized pullback at
0.5mm/s was performed to elucidate the mechanisms of
the ST. The proximal LAD showed a positive vessel wall
remodeling with maximum diameters within the external
elasticmembrane(EEM)atbothstentbordersof4.5mmand
3.5mm, respectively (Figures 2(a), 2(b)). The vessel lumen,
however, was encroached by a huge atherosclerotic plaque
that comprised 59% to 74% of the measured area within
the EEM and extended considerably beyond the outer stent
margins. Near the distal part of the implanted stent, a severe
stent fracture (SF) was found with complete strut separation
over a wide distance (Figures 3(a)–3(d)). The cross-sectional
lumen area (CSA) at the site with missing struts was onlyCase Reports in Medicine 3
2.1mm2. The decision was made to enlarge the stent with
the balloon angioplasty. The noncompliant Mercury NC
3.0×20mm balloon (Abbot, Redwood City, Calif, USA) was
inﬂated successively across the stented segment up to 20 At
with the resulting CSA of ≥ 6.5mm2. The ﬁnal angiographic
result appeared excellent (Figure 2(d)) and, therefore, the
PCI was completed without additional stent placement.
The patient was then admitted to the CCU where
tests addressing the antiaggregatory platelet function were
carried out. The point-of-care testing using VerifyNow
(Accumetrics, San Diego, Calif, USA) demonstrated a good
antiaggregatory eﬀect of aspirin with the ARU of 390
(normally, 620–672) and, on the contrary, a poor response
to clopidogrel with the PRU of 245 (normally, 194–418) and
only 10% inhibition, suggesting the clopidogrel resistance.
The daily dose of clopidogrel was raised to 150mg for the
next year.
The further hospital course was uneventful. She experi-
enced no additional adverse events until her outpatient visit
6 months later.
3. Discussion
We have described the case of the young patient in whom the
SES was implanted on the culprit LAD at primary PCI for
the acute MI. Nine month later she suﬀered from the re-MI
due to the late ST. Several factors were found that may have
contributed to the ST: (1) suboptimal PCI technique, (2) SF,
and (3) clopidogrel resistance.
A rigorous PCI technique is a crucial measure to prevent
the ST in the DESs. It is recommended to predilate the lesion
carefully with a balloon shorter than planned stent length, to
achieve a stent-to-artery ratio of 1.1 : 1 at nominal pressure,
to cover the entire lesion with the stent including portions
injured by balloon inﬂations, to expand the stent with high
pressure inﬂations using a short noncompliant balloon, and
to obtain a residual stenosis of <10% or CSA ≥ 5.0mm2 [2,
3]. In our case, several procedural steps should be criticized.
First, the lesion was pre-dilated with the balloon longer than
the chosen stent. Next, rather a small (i.e., axial geographic
miss) and short stent (i.e., longitudinal geographic miss)
was implanted leaving a huge portion of the atherosclerotic
plaque outside the stent boundaries. If the IVUS had been
performed at initial PCI, we would have taken the advantage
ofthepositivevesselremodelingforamoreaggressivemedia-
to-media stent sizing. Finally, the SES in our patient was
not properly expanded as we relied on a seemingly good
angiographic result.
In our patient, a wide displacement of the fractured
stent fragments accompanied by the luminal collapse was
discovered at repeat catheterization. The SF has been
found in 1.7–18.6% of all implantations 2–699 days after
the index PCI [4, 5]. Stents prone to break are often
overexpanded and overlapped, those placed into tortuous
arteries with angulated segments and diﬀuse atherosclerosis,
in the RCA, saphenous vein grafts, and myocardial bridges.
Target lesion in our case, located in the diﬀusely diseased
and angulated LAD, was certainly not well prepared for
the stenting. SESs, in particular, are supposed to rupture
more readily since their potent antiproliferative ability may
leave stent struts unsupported by the neointimal tissue
[6].
Platelets are believed to play a pivotal role in the devel-
opment of thrombosis following plaque rupture occurring
spontaneously or at PCI. Results from the CREST [7]
and RECLOSE trials [8] have clearly demonstrated that
high posttreatment platelet reactivity and incomplete P2Y12
receptor inhibition are important risk factors for the ST.
Recently, Price and coworkers [9] pointed out that patients
with post-treatment PRU greater than the cutoﬀ value had
signiﬁcantly higher rates of cardiovascular death and ST
( 4 . 6 %v e r s u s0 %i nc o n t r o l s ,P = .004). Likewise, the PRU
measured in our patient indicated a poor antiaggregatory
responsetoclopidogreland,asaresult,thefailureofthedrug
to prevent thrombotic events after the stenting.
In treating our patient, we had to address two major
issues, stent obstruction and clopidogrel resistance. Using a
plain balloon angioplasty, we achieved an acceptable vessel
lumen with the CSA well over 5.0mm2 without inserting
another metallic stimulus into the patient’s thrombotic
environment. On top of the mechanical intervention, we
doubled empirically the dose of clopidogrel for the next
year.Antiplateleteﬃcacyofincreasedclopidogrel dosagewas
not evaluated after dose increase; however, lack of clinical
events after dose increase suggested better antiplatelet eﬀect
of clopidogrel.
Our patient had a very premature coronary artery
disease. While her risk factors might explain the early
onset of the disease, presence of hypercoagulable state was
not evaluated and could have contributed to her MI on
both occasions. Several physiologic and pathologic condi-
tions, such as pregnancy, oral contraceptives, homocystein,
antiphospholipid antibodies, antithrombin deﬁciency, low
protein C and S, and some genetic mutations (e.g., factor
V Leiden) are often associated with a hypercoagulable state
promoting thrombotic events [10–12]. However, the eleva-
tion of homocystein during MI may be related to an increase
in the acute-phase reactant proteins and the measurements
should be deferred for at least 6 weeks to determine the
true baseline level [11]. Finally, it remains unclear why many
subjects who are positive for antiphospholipid antibodies do
not develop thrombosis. Although all those patients showed
the evidence of endothelial activation, only platelet activ-
ity diﬀered between thrombotic and nonthrombotic cases
predicting the ineﬀectiveness of the additional anticoagulant
therapy [12].
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